Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pozen up on AZN pain program, deal

POZN gained $2.78 (28%) to $12.26 on news that it and partner AstraZeneca (LSE:AZN; AZN) will begin a Phase

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE